Phases of drug development

Overview

Drug development progresses through a structured sequence - preclinical (laboratory/animal studies), then Phase I (small-scale human safety/pharmacokinetics, typically healthy volunteers), Phase II (efficacy and dose-finding in a small patient population), Phase III (large-scale randomised trials confirming efficacy/safety before regulatory approval), and Phase IV (post-marketing surveillance after approval) - each phase answering progressively more definitive questions with progressively larger patient numbers
Foundational knowledge underlying understanding of the evidence base (and its limitations) for any medication, and relevant to understanding why newly approved drugs carry more residual uncertainty than long-established agents

Each phase is designed to answer a specific question before proceeding to a larger, more resource-intensive stage - this staged approach protects trial participants and the eventual patient population from unacceptable risk by establishing basic safety before larger efficacy testing, and reasonable efficacy signal before very large-scale, expensive confirmatory trials

Phase III trial population characteristics (inclusion/exclusion criteria, typical patient demographics enrolled) should be considered when extrapolating trial evidence to an individual patient who may differ substantially from the trial population (e.g. significant comorbidity, extremes of age, pregnancy - groups often excluded from earlier-phase trials)

Phase IV post-marketing surveillance is essential for detecting rare adverse effects not captured in the necessarily smaller pre-approval trial populations, given that some adverse effects only become statistically detectable once a drug is used in much larger, more diverse real-world populations
New drug approval does not mean complete safety/efficacy certainty - some safety signals only emerge after wider post-marketing use, explaining why newly approved drugs warrant somewhat more cautious, closely monitored use initially
Phase IV post-marketing surveillance detecting rare adverse effects (e.g. drugs withdrawn after post-marketing safety signals emerged), trial population generalisability limitations, staged risk-escalation trial design rationale
Rare but serious adverse effects sometimes only become apparent during Phase IV post-marketing surveillance, after a drug has been used in a much larger and more diverse population than was feasible in pre-approval trials - this is why newly approved medications, despite having passed rigorous Phase III testing, still warrant somewhat more cautious prescribing and vigilance for unexpected adverse effects than long-established agents

3 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.